| __timestamp | Incyte Corporation | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3004000 | 5758000 |
| Thursday, January 1, 2015 | 26972000 | 8423000 |
| Friday, January 1, 2016 | 58187000 | 11986000 |
| Sunday, January 1, 2017 | 79479000 | 15215000 |
| Monday, January 1, 2018 | 94123000 | 15356000 |
| Tuesday, January 1, 2019 | 114249000 | 16660000 |
| Wednesday, January 1, 2020 | 131328000 | 52459000 |
| Friday, January 1, 2021 | 150991000 | 75061000 |
| Saturday, January 1, 2022 | 206997000 | 87221000 |
| Sunday, January 1, 2023 | 255000000 | 83779000 |
| Monday, January 1, 2024 | 312068000 |
Igniting the spark of knowledge
In the competitive landscape of biopharmaceuticals, understanding cost structures is crucial. Over the past decade, Incyte Corporation and Supernus Pharmaceuticals, Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Incyte's cost of revenue surged by over 8,300%, reflecting its aggressive expansion and increased production capabilities. In contrast, Supernus Pharmaceuticals experienced a more modest growth of around 1,400% in the same period, indicating a more conservative approach.
By 2023, Incyte's cost of revenue was approximately three times that of Supernus, highlighting its larger scale of operations. This disparity underscores the different strategic paths these companies have taken. As investors and industry analysts look to the future, these trends offer valuable insights into the operational efficiencies and market strategies of these two industry players.
AbbVie Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Pfizer Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Incyte Corporation vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Ionis Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Alkermes plc vs Supernus Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses